Warther Private Wealth LLC Sells 500 Shares of AstraZeneca PLC (NASDAQ:AZN)

Warther Private Wealth LLC lessened its stake in AstraZeneca PLC (NASDAQ:AZN) by 11.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,698 shares of the company’s stock after selling 500 shares during the quarter. Warther Private Wealth LLC’s holdings in AstraZeneca were worth $288,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of AZN. Stratos Wealth Advisors LLC grew its position in AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after purchasing an additional 133 shares in the last quarter. Bruce G. Allen Investments LLC lifted its holdings in AstraZeneca by 19.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock worth $67,000 after purchasing an additional 138 shares in the last quarter. Carnegie Investment Counsel boosted its stake in AstraZeneca by 0.8% in the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock worth $1,347,000 after purchasing an additional 138 shares during the period. CANADA LIFE ASSURANCE Co grew its holdings in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares in the last quarter. Finally, Sunpointe LLC increased its position in shares of AstraZeneca by 4.5% during the second quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock valued at $267,000 after buying an additional 147 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AstraZeneca stock opened at $75.72 on Friday. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The firm has a market cap of $234.78 billion, a P/E ratio of 36.67, a P/E/G ratio of 1.43 and a beta of 0.46. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm has a 50-day moving average of $80.59 and a 200-day moving average of $78.39.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. The firm had revenue of $12.45 billion for the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period last year, the company earned $1.08 EPS. Sell-side analysts expect that AstraZeneca PLC will post 4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

AZN has been the subject of several recent analyst reports. TD Cowen boosted their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.